SUNVOZERTINIB - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for sunvozertinib and what is the scope of patent protection?
Sunvozertinib
is the generic ingredient in one branded drug marketed by Dizal Jiangsu and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.Sunvozertinib has thirty patent family members in sixteen countries.
Summary for SUNVOZERTINIB
| International Patents: | 30 |
| US Patents: | 3 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Clinical Trials: | 10 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for SUNVOZERTINIB |
| DailyMed Link: | SUNVOZERTINIB at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for SUNVOZERTINIB
Generic Entry Date for SUNVOZERTINIB*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for SUNVOZERTINIB
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Dizal (Jiangsu) Pharmaceutical Co., Ltd. | PHASE3 |
| Dizal (Jiangsu) Pharmaceutical Co., Ltd. | PHASE1 |
| Dizal (Jiangsu) Pharmaceutical Co., Ltd. | PHASE2 |
US Patents and Regulatory Information for SUNVOZERTINIB
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dizal Jiangsu | ZEGFROVY | sunvozertinib | TABLET;ORAL | 219839-001 | Jul 2, 2025 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Dizal Jiangsu | ZEGFROVY | sunvozertinib | TABLET;ORAL | 219839-002 | Jul 2, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Dizal Jiangsu | ZEGFROVY | sunvozertinib | TABLET;ORAL | 219839-002 | Jul 2, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for SUNVOZERTINIB
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| South Korea | 20250046340 | ⤷ Start Trial | |
| Mexico | 2020007947 | INHIBIDORES DE ERBB/BTK. (ERBB/BTK INHIBITORS.) | ⤷ Start Trial |
| China | 111747934 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
